Dual Aging Therapy Boosts Lifespan 70% in Preclinical Study
Clearing zombie cells then restoring stem cell activity produced far greater lifespan gains than either approach alone.
20 articles
Clearing zombie cells then restoring stem cell activity produced far greater lifespan gains than either approach alone.
Activating three Yamanaka factors โ OCT4, SOX2, and KLF4 โ appears to reverse epigenetic aging in human eye cells, marking a milestone in rejuvenation medicine.
New research shows senescent cells play a vital healing role in youth โ and losing this response may explain why wounds heal slower with age.
Ossium Health is banking donor bone marrow for on-demand transplant, targeting immune aging as a future healthspan intervention.
A dual therapy clearing senescent cells and restoring stem cell function dramatically extended mouse lifespan in a new preclinical study.
Immorta Bio combines senolytics and stem cell revival with AI to achieve 70%+ lifespan extension in animal models.
New research reveals primary and secondary senescent cells behave differently, opening targeted paths to slow aging at the cellular level.
A new MIT-led therapy uses mRNA nanoparticles to rewire immune cells from within, achieving complete tumor regression in most treated mice.
Rockefeller scientists reprogrammed blood stem cells to produce rare broadly neutralizing antibodies, offering a potential one-time immunity platform.
New research proposes the immune system actively controls gut microbiome diversity, and that aging-related immune decline drives dysbiosis.
Researchers discovered how to restore tumor-killing power in worn-out immune cells by switching off just two genes.
Immorta Bio is using AI to move beyond disease treatment toward restoring youthful biology by clearing senescent cells and reviving stem cells.
When tumors hide from killer T cells, they accidentally expose themselves to helper T cells that trigger a lethal iron-driven cell death process.
UCLA researchers eliminated senescent immune cells in mice, dramatically reversing liver damage even without diet changes.
Belgian biotech Coultreon raises $125M to advance an oral SIK3 inhibitor that rebalances inflammation rather than suppressing immunity outright.
Life Biosciences begins groundbreaking human trials testing cellular reprogramming therapy to reverse aging at the cellular level.
New research reveals senescent cells have both harmful and protective roles, pushing anti-aging science toward targeted removal strategies.
A stem cell therapy for geographic atrophy showed sustained vision gains and retinal repair three years after a single injection in a Phase 1/2a trial.
Daewoong Pharmaceutical buys Turn Bio's ERA platform, using mRNA to partially reverse cellular aging without tumor risk.
Swiss partnership launches cellular avatars that predict immune responses and aging patterns using AI-powered modeling.